BIOPOR Bioporto A/S

BioPorto A/S - Annual General Meeting

BioPorto A/S - Annual General Meeting

April 14, 2020

Announcement no. 9

BioPorto A/S - Annual General Meeting

Today, BioPorto A/S held its Annual General Meeting during which the report on the Company’s activities was reviewed and the 2019 Annual Report was adopted. The proposed profit/loss allocation was also adopted and discharge of liability was granted to the Board of Directors and the Executive Management. Finally, the remuneration for the Board of Directors was approved.

Thomas Magnussen, Torben A. Nielsen, Kirsten Aarup Drejer, Christopher Lindop and Michael S. Singer were re-elected as members of the Board of Directors. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its Chairman and Torben A. Nielsen as its Vice Chairman. 

The proposals from the Board of Directors under item 6 of the agenda were all adopted, and included: a) Amending the Articles of Association regarding shareholders’ notification of attendance for a general meeting, b) Amending the standard agenda for the Annual General Meeting in Article 8 in the Articles of Association, c) Renewing the authorization to issue warrants for up to DKK 2,500,000 following decision by the Board of Directors to amend its original proposal of up to DKK 6,600,000 shares, d) Approving the Company’s revised Remuneration Policy and e) Authorization to the Chairman of the general meeting.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

Hellerup, April 14, 2020

BioPorto A/S

The Board of Directors

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
14/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med...

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL 26. september, 2025Meddelelse BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL KØBENHAVN, DANMARK og BOSTON, MA, USA, 26. september – BioPorto A/S (“BioPorto” eller “Selskabet”) (CPH:BIOPOR), annoncerer sin støtte til konferencer med fokus på pædiatriske organtransplantationer og intensiv behandling indenfor nefrologi. Kliniske forskere præsenterer posters, resuméer og nye publikationer, hvor NGAL anven...

 PRESS RELEASE

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL...

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acut...

 PRESS RELEASE

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæ...

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren 11. september, 2025Meddelelse US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. september – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerer det kommende virtuelle arrangement fra US News & World Report: “New Frontiers in Kidney Care”, som vil fokusere på akut og kronisk nyresygdom globalt samt de tiltag, der kan sikre de bedst mulige behandlingsresultater inden for nyresundhed. Webinaret afholdes tors...

 PRESS RELEASE

US News & World Report Webinar “New Frontiers in Kidney Care” features...

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run live on ...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 1. september 2025 Meddelelse nr. 20                                                                          Tildeling af Warrants København, Danmark, den 1. september 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 5.000.000 warrants til et medlem af Selskabets direktion. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,28 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i S...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch